The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1621
ISSUE 1621
April 5, 2021
Issue 1621
- An EUA for Bamlanivimab and Etesevimab for COVID-19
- Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
- Semaglutide (Ozempic) for Weight Loss
- Low-Dose Colchicine for Coronary Artery Disease
- In Brief: Hypertension with Erenumab (Aimovig)
- Ripretinib (Qinlock) for GIST (online only)
- COVID-19 Vaccine Comparison Chart (online only)
| Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
An EUA for Bamlanivimab and Etesevimab for COVID-19
April 5, 2021 (Issue: 1621)
The FDA has issued an Emergency Use Authorization
(EUA) for Lilly's investigational monoclonal antibodies
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)
to be administered together for treatment of
mild to moderate COVID-19 in patients ≥12 years old
who weigh ≥40 kg and are at high risk of progressing
to severe disease and/or hospitalization (see Table 1).
Bamlanivimab received an EUA for use as monotherapy
in such patients in November 2020. Regeneron's
investigational monoclonal antibodies casirivimab
(REGN10933) and imdevimab (REGN10987) are also
authorized for use together for the same indication.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1621
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
